Patent foramen ovale closure: A prospective UK registry linked to hospital episode statistics

PLoS One. 2022 Jul 14;17(7):e0271117. doi: 10.1371/journal.pone.0271117. eCollection 2022.

Abstract

Aims: PFO closure is a percutaneous intervention, which aims to reduce risk of recurrent stroke by preventing paradoxical embolism. The objective of this study was to measure procedural safety and longer-term effectiveness of PFO closure in a UK setting.

Methods and results: Prospective registry data from patients with cryptogenic stroke eligible for PFO closure were collected for up to 2 years and linked to routine data sources for additional follow-up. Outcomes of interest included procedural success rate, health related quality of life, and longer-term death and neurological event rates. A total of 973 PFO closure procedures in 971 patients were included in analysis. Successful device implantation was achieved in 99.4 [95% CI 98.6 to 99.8]% of procedures, with one in-hospital death. During median follow-up of 758 (Q1:Q3 527:968) days, 33 patients experienced a subsequent neurological event, 76% of which were ischaemic in origin. Neurological event rate was 2.7 [95%CI 1.6 to 3.9]% at 1-year (n = 751) and 4.1 [95% CI 2.6 to 5.5]% at 2-years (n = 463) using Kaplan-Meier analysis. Improvements in patient quality of life (utility and visual analogue scale) were observed at 6-weeks and 6-months follow-up.

Conclusion: Our observational study demonstrates that PFO closure for prevention of recurrent stroke is a relatively safe procedure but in routine clinical practice is associated with a slightly higher risk of recurrent neurological events than in randomised trials. We hypothesize that our study enrolled unselected patients with higher baseline risk, who were excluded from randomised trials, but who may benefit from a similar relative reduction in risk from the intervention.

Publication types

  • Observational Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiac Catheterization / methods
  • Foramen Ovale, Patent* / complications
  • Foramen Ovale, Patent* / surgery
  • Hospital Mortality
  • Hospitals
  • Humans
  • Quality of Life
  • Recurrence
  • Registries
  • Secondary Prevention / methods
  • Septal Occluder Device*
  • Stroke* / epidemiology
  • Stroke* / etiology
  • Stroke* / prevention & control
  • Treatment Outcome
  • United Kingdom / epidemiology

Grants and funding

Newcastle upon Tyne Hospitals NHS Foundation Trust (NuTH), the employing institution of IW, KK, HC and AJS, is contracted as External Assessment Centre to the NICE Medical Technologies Evaluation Programme (MTEP), contract numbers NICE847 (2014-1018) and NICE EACFA18-21 (2018-2022). NuTH is contracted by Academic Health Science Network North East and North Cumbria to develop methodologies and case studies relating to "evaluation in practice", in the context of using routine healthcare datasets and, where appropriate, clinical registries, to assess outcomes and adoption of novel interventions (contract number SN2780933_2).